Denali Therapeutics Inc. (DNLI) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 37 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 3, 2026after close 34 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Thu, Feb 26, 2026after close 57 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Tue, May 6, 2025after close 36 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 million" exhibit
Q3 FY2026 "Five TransportVehicle™ (TV) programs expected to generate data in 2027: zafinofusp alfa (ETV:SGSH), DNL593 (PTV:PGRN), DNL628 (OTV:MAPT), DNL921 (ATV:Abeta) and DNL952 (ETV:GAA)" exhibit
Q3 FY2026 "Fourth-quarter 2026 net product revenue is expected to be $30.0 million to $32.0 million." exhibit
Q3 FY2026 "Data from the COMPASS study are expected in the first half of 2028." exhibit
Q3 FY2026 "Data are expected in the first half of 2027." exhibit
Q2 FY2026 "Projected third-quarter 2026 AVLAYAH net product revenue is $10.0 million to $12.0 million." exhibit
Q2 FY2026 "Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for zafinofusp alfa for Sanfilippo syndrome type A in 2027." exhibit
Q2 FY2026 "Denali now expects results from the study in 2027, updated from its prior expectation of results by the end of 2026." exhibit
Q2 FY2026 "Dosing of participants with late-onset Pompe disease began in the Phase 1 study of DNL952 in the second quarter of 2026, and initial clinical data are expected in 2027." exhibit
Q2 FY2026 "Initial clinical biomarker data from the ongoing Phase 1b study of DNL628 in participants with Alzheimer’s disease are expected in the first half of 2027. 2 DNL921 (ATV:Abeta) for Alzheimer's disease DNL921 is an investigational Antibody TransportVehicle ™ (ATV)-enabled antibody designed for systemic delivery across the blood-brain barrier to target amyloid plaques in Alzheimer's disease." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DNLI
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DNLI

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

DNLI earnings date badge

HTML

<a href="https://veritasdata.dev/company/DNLI/"><img src="https://veritasdata.dev/embed/DNLI.svg" alt="DNLI earnings date" width="240" height="56"></a>

Markdown

[![DNLI earnings date](https://veritasdata.dev/embed/DNLI.svg)](https://veritasdata.dev/company/DNLI/)

Script

<script async src="https://veritasdata.dev/embed/DNLI.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DNLI"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.